Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.
10x Genomics has entered into a multi-project research agreement with Fred Hutchinson Cancer Center (Fred Hutch) for advancing single cell as well as spatial platforms in solid tumours and blood cancers.
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) across selected Latin American markets.
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and antibody-drug conjugates (ADCs) across multiple tumour types.
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Genialis has teamed up with Inventia Life Science to enhance the testing of pancreatic cancer treatments and match them to the patients who are likely to benefit.
Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the development of precision therapies in solid tumours.
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.